Home / Health / New Blood Test Promises Earlier Cancer Detection
New Blood Test Promises Earlier Cancer Detection
5 Jul
Summary
- A new law enables Medicare coverage for multi-cancer early detection blood tests.
- Early detection dramatically improves cancer survival rates for patients.
- MCED technology detects cancer signals in blood, including hard-to-find cancers.
The recent enactment of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act signifies a major advancement in cancer care. This law establishes a pathway for Medicare to cover FDA-approved multi-cancer early detection (MCED) tests.
These innovative blood tests utilize recent progress in genomics and machine learning to identify cancer signals. They show particular promise in detecting early stages of pancreatic, ovarian, and esophageal cancers, which currently have low survival rates.
Catching cancer early is crucial, as localized tumors are far more treatable than those that have metastasized. For instance, the five-year survival rate for Stage 1 breast cancer is over 99%, drastically dropping to 33% for Stage 4.
MCED screenings are expected to be particularly beneficial for seniors, who account for the majority of cancer diagnoses. By 2030, approximately 70% of cancers will be diagnosed in individuals over 65.
Ensuring equitable access to these life-saving screenings is paramount. They must be available in rural clinics, community health centers, and mobile health programs, not just major hospital systems.
